Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
–JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio
-JANX007 is the Company’s lead prostate cancer program and primary development priority
-JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux’s tumor-activated technology platform to selectively activate T cells in the tumor microenvironment.
Janux is building a portfolio of tumor-activated PSMA therapies designed to address multiple treatment settings and mechanisms of immune engagement. Early clinical data from JANX007 have demonstrated what Janux believes is potentially a best-in-class clinical profile in mCRPC, including a favorable safety profile with no Grade 3 cytokine release syndrome observed at clinically relevant dose levels using the current CRS mitigation strategy. These data continue to guide Janux’s development strategy in prostate cancer. JANX014 represents an exploratory extension of the strategy, emerging from platform work initiated in early 2024 evaluating multiple PSMA-directed approaches. JANX014 will also explore potential future use cases where enhanced safety margins and ease of administration may be particularly important.
“We are pleased to have initiated clinical evaluation of JANX014,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics. “JANX007 remains our lead prostate program, and we believe it has established a strong clinical foundation for PSMA-directed TRACTr therapy. Insights from programs such as JANX007 and JANX008 have informed our continued platform development.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?